Pharmacokinetics of cefiderocol during extracorporeal membrane oxygenation: A case report.

Humans Extracorporeal Membrane Oxygenation / methods Anti-Bacterial Agents / therapeutic use Cephalosporins / therapeutic use Monobactams Cefiderocol
ECMO cefiderocol extracorporeal membrane oxygenation microbial drug resistance pharmacokinetics

Journal

Perfusion
ISSN: 1477-111X
Titre abrégé: Perfusion
Pays: England
ID NLM: 8700166

Informations de publication

Date de publication:
05 2023
Historique:
medline: 2 5 2023
pubmed: 1 3 2023
entrez: 28 2 2023
Statut: ppublish

Résumé

Patients with extracorporeal membrane oxygenation (ECMO) support do frequently receive broad-spectrum antibiotics, due to the high frequency of infection by multidrug resistant microorganisms. The extracorporeal circuit can alter the pharmacokinetics (PK) of administered drugs, and in the case of antibiotics this may lead to treatment failure. Cefiderocol is a new cephalosporin that exhibits excellent in vitro activity against many multidrug-resistant (MDR) microorganisms, but there is no published data about the modifications of its PK in patients with ECMO support. Herein we report the results of a pharmacokinetic investigation of cefiderocol in a critically ill patient receiving extracorporeal respiratory support.

Identifiants

DOI: 10.1177/02676591231160462 PMID: 36853601
pubmed: 36853601
doi: 10.1177/02676591231160462
doi:

Substances chimiques

Anti-Bacterial Agents 0
Cephalosporins 0
Monobactams 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

40-43

Auteurs

Jordi Riera (J)

Critical Care Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Sepsis, Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.
Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
ORCID: 0000-0002-1738-4448

Laura Domenech (L)

Pharmacy Department, Vall D'Hebron University Hospital, Barcelona, Spain.

Sonia García (S)

Pharmacy Department, Vall D'Hebron University Hospital, Barcelona, Spain.

Alba Pau (A)

Pharmacy Department, Vall D'Hebron University Hospital, Barcelona, Spain.
ORCID: 0000-0001-9773-8690

Manuel Sosa (M)

Critical Care Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Sepsis, Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.

Josep Domenech (J)

Critical Care Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Sepsis, Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.

Clara Palmada (C)

Critical Care Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Sepsis, Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.

Pau Torrella (P)

Critical Care Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Sepsis, Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.

Ariadna Sánchez (A)

Critical Care Department, Vall d'Hebron University Hospital, Barcelona, Spain.

Anna Lamora (A)

Critical Care Department, Vall d'Hebron University Hospital, Barcelona, Spain.

Elisabet Gallart (E)

Critical Care Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Sepsis, Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.

Pilar Girón (P)

Critical Care Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Sepsis, Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.

Xavier Nuvials (X)

Critical Care Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Sepsis, Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.

Ricard Ferrer (R)

Critical Care Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Sepsis, Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Pharmacokinetics of cefiderocol during...
questionsmedicales.fr › Procédures de chirurgie opératoire › Circulation extracorporelle › Oxygénation extracorporelle sur oxygénateur à membrane › Pharmacokinetics of cefiderocol during...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Pharmacokinetics of cefiderocol during...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Céphalosporines › Pharmacokinetics of cefiderocol during...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Monobactames › Pharmacokinetics of cefiderocol during...